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Abstract 
Background: Previous studies showed that after breast-conserving surgery for breast cancer, radiotherapy may be applied to the portion 
of the breast where the primary tumour was removed (partial breast irradiation (PBI), avoiding the irradiation of the whole breast. We 
developed a procedure of PBI consisting of a single high dose of radiotherapy of 21 Gy with electrons equivalent to 58–60 Gy in 
fractionated doses, delivered during the surgical session by a mobile linear accelerator, positioned close to the operating table. 
Patients and methods: From July 1999 to December 2006, 1246 patients with primary carcinoma of less than 2.5-cm maximum 
diameter, mostly over 48 years, were treated with electron intra-operative radiotherapy (ELIOT) at a single dose of 21 Gy. 
Results: After a follow-up from 0.3 to 94.7 months (median 26), 24 (1.9%) patients showed a local recurrence and 22 developed distant 
metastases. Sixteen patients died, seven from breast carcinoma and nine from others causes. The five-year crude survival was 96.5%. 
Six (0.5%) developed severe breast fibrosis, which resolved in 2–3 years. An additional 40 patients suffered for mild fibrosis. Cosmetic 
results were good. 
Conclusions: Electron intra-operative radiotherapy is a safe method for treating conservatively operated breasts and avoids the long 
period of post-operative radiotherapy, greatly improving the quality of life and reduces the cost of radiotherapy. ELIOT markedly reduces 
the radiation to normal surrounding tissues and deep organs. Results on short- and medium-term toxicity are good. Data on local control 
are encouraging. 
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Partial breast irradiation (PBI) after conservative surgery, the 
pin-point use of radiation fields on a limited involved portion of 
the breast rather than the whole organ, is a procedure that is 
gaining ground in breast cancer treatment with many studies 
showing encouraging results [1–4]. Another important theme 
under discussion is intra-operative radiotherapy (IORT), which 
has been utilized in the last few decades to irradiate, with an 
external single dose, different types of tumours, mainly in the 
abdominal cavity during surgery [5]. The limitation of its use, 
due to the need to transfer the patient from the surgical theatre 
to the radiotherapy department during surgery, was recently 
overcome by the availability of mobile linear accelerators, which 
can enter the surgical theatre. 
In 1999 we developed the idea of combining the two procedures 
(PBI and IORT) to irradiate the breast during conserving surgery 
in a single session, and we started a series of clinical studies 
whose preliminary results were previously reported. With the 
new technique, which we defined electron intra-operative 
therapy (ELIOT), the mobile linear accelerator delivers a single 
dose of radiation with electrons to the involved quadrant of the 
breast during surgery, shortening the radiotherapy course from 
six weeks to one single session during surgery [6–9]. 
We describe here the results from a series of 1246 breast 
cancer patients treated with ELIOT from 1999 to 2006. 
 
Patients and methods 
From July 1999 to December 2006, 1246 breast cancer patients 
(mean age 57 years, range 33–80) were treated with ELIOT 
after breast-conserving surgery. All patients had unicentric 
primary carcinoma, with a maximum largest diameter of 2.5 cm 
on clinical or radiological examination. Before reaching the full 
dose of 21 Gy, 33 patients were treated with ELIOT at various 
doses, progressively ranging from 10 to 19 Gy as part of the 
initial dose-finding study. The remaining 1213 patients received 
21 Gy prescribed at the 90% isodose as sole radiation 
treatment. Most of the patients were over 48 years, due to the 
inclusion criteria we established for our protocol. As we are 
conducting ‘separate’ a randomized trial comparing ELIOT 
single dose with traditional external radiotherapy, all eligible 
patients were normally asked to participate in that trial. The 
patients described in the present paper are those that either did 
not chose to enter the randomized trial or did not fulfil the 
eligibility criteria. They are many in number, but this reflects the 
fact that more than 3000 patients are operated each year in IEO 
for breast cancer. The randomized trial criteria were tightly 
observed when treating these patients. Many of the excluded 
patients requested to be treated by the ELIOT technique. These 
patients were clearly advised that the procedure was 
experimental, and they then signed an informed consent form, 
in which they acknowledged their understanding of the 
experimental nature of their treatment. The characteristics of the 
patient population are summarized in Tables 1 and 2. Patients 
who declined to sign the informed consent form were treated 




As regards surgery, 1125 patients received quadrantectomy 
with axillary sentinel node biopsy; of these, 888 (71.3%) had a 
negative sentinel node and so axillary dissection was not 
performed, 358 (28.7%) showed a metastatic sentinel node and 
311 of these received complete axillary dissection, while 47 
patients with micro-metastatic involvement, being part of a 
randomized study, did not undergo axillary dissection. Eighty-
five patients received quadrantectomy with immediate complete 
axillary dissection due to clinically positive nodes. Thirty-two 
patients received simple quadrantectomy, either because the 
carcinoma was minimal or due to difficult general conditions. 




According to the tumour site and size and breast size and 
shape, wide breast resection was done according to the 
standard quadrantectomy. The ELIOT procedure does not 
interfere with the oncologic criteria of 'classic' breast-conserving 
surgery (BCS) in which 1.5–2 cm grossly free margins of 
resection are required. 
After the tumour removal, the wide mobilization of the mammary 
gland from the fascia of the pectoralis major and, superficially, 
from the skin, represents a critical step, permitting the optimal 
exposure of the 'target' to the radiation beam. The deep surface 
of the breast is easily mobilized from the fascia of the pectoralis 
major muscle for at least 4–5 cm around the tumour bed to 



















Table 1: Characteristics of the 1246 ELIOT patients 
 
 
Table 2: ELIOT patients July 1999-December 2006 



















approximate the parenchyma of the central area and to expose 
the mammary parenchyma to the radiation beam. The 
superficial margins of the parenchyma must also be carefully 
separated from the subcutaneous tissue at the level of the 
anterior adipose lamina for 3–5 cm in every direction. 
Thoracic wall protection 
To minimize the radiation delivered to the thoracic wall and to 
guarantee the delivery of the full radiation dose to the gland, a 
dedicated disk of lead and aluminium, available in various 
diameters (4–6 cm), is used as a protective device. The disk is 
inserted (lead down, aluminium up) in the space between the 
gland and the pectoralis muscle. To allow the best protection of 
the thoracic wall, the disk must be greater in size than the 
breast target size. According to the extent of the skin incision 
and to the anatomical local conditions whenever possible, the 
largest possible disk is placed exactly under the mammary 
target to be irradiated. 
 
Breast gland reconstruction 
The gland must be reconstructed over the disks to expose the 
correct portion of the breast to the radiation beam, thereby 
avoiding excessive inhomogeneity in the shape of the target 
volume. The electron beam energy is chosen on the basis of the 
thickness of the target volume, and the best dose distribution of 
radiotherapy in the gland is achieved if the thickness of the 
irradiated target remains as homogeneous as possible. The 
gland thickness is then measured using a simple needle 
(perpendicularly inserted through the breast target until the hard 
surface of the disk can be felt), and the correct electron energy 
is selected. The exact site where the tumour was located is 
marked by ink on the mammary gland surface. This point 
represents the centre of the target for the irradiation. 
IORT collimator placement and connection to the 
linear accelerator 
The sterile polymethyl methacrylate (Perspex; Hitesys SpA, 
Aprilia, Italy) collimator of the linear accelerator (LINAC) is 
introduced through the skin incision and placed directly in 
contact with the breast target. The collimator is centred on the 
previous ink marker on the mammary gland surface. Correct 
positioning of the collimator is fundamental to guarantee the 
coverage of the entire target volume. 
The portion of the breast that needs to be irradiated (clinical 
target volume) is generally an area of 4–6 cm of diameter 
around the cancer resection site. The collimator diameter is 
selected on the basis of the choice of the area to be treated to 
ensure the adequacy of the coverage of the entire tumour bed 
plus a safe margin. The collimator is placed directly in contact 
with the breast gland, after moving the LINAC by remote control 
to reach the operating table. 
 
Radiotherapy 
Electron intra-operative radiotherapy technique has been 
described in previous papers [6–9]. Briefly, two mobile linear 
accelerators (Figure 1) were used to deliver electrons, a Novac7 
(Hitesys Srl, Latina, Italy) and a Liac (Info&Tech, Roma, Italy), 
installed in two different operating rooms. The two linear 
accelerators, which can be easily manoeuvred by means of 
motors acting on the wheels and on the robotic arm, deliver 
electrons at the following different nominal energies: 3, 5, 7 and 
9 MeV (Novac7) and 4, 6, 8 and 10 MeV (Liac). The collimation 
of the beam is achieved by a hard-docking system, consisting of 
perspex applicators, 5-mm thick. The flat-ended and bevelled 
(15° up to 45°) round applicators have a diameter ranging from 
4 to 12 cm. The nominal source to surface distance (SSD) is 
80–100 cm for Novac7 and 60 cm for Liac. The radiation 
protection is obtained by a primary beam stopper, consisting of 
a trolley-mounted 1.5-cm-thick lead shield and some mobile 1.5-
cm-thick lead shielding (100 cm long, 150 cm high). 
In the Quality Assurance programme for those dedicated linear 
accelerators, we have implemented an in vivo dosimetry 
procedure, aimed at controlling the dose delivered to the patient 
[10]. 
Every patient was evaluated one, three, six and 12 months after 
surgery, and thereafter every six months, to look for early, 
intermediate and late complications. The follow-ups ranged from 




Adjuvant treatments were given according to the rules and 
protocols in force during the period of patient accrual at the 
European Institute of Oncology. 




















Figure 1: The linac used for ELIOT.
Eight-hundred-and-seven patients received endocrine 
treatment, 128 patients were treated with chemotherapy, 156 




We have observed 30 cases of true recurrences (2.4%). The 
median time of the appearance of local recurrences was 26.7 
months from the operation. More than 70% were detected by 
radiological examination (mammography, ultrasound and RM). 
These 30 patients were either given a second breast-conserving 
operation (12 cases) or a total mastectomy (18 cases). Twenty-
eight patients are well without evidence of disease. One patient 
developed multiple metastases two years after the second 
operation and one patient developed liver metastases. Both 
patients were stabilized after systemic treatment. 
There were 11 (0.9%) second primary carcinomas in other 
quadrants. Eight cases had a second breast resection and 3 
underwent total mastectomy. One case developed lung 
metastases and died from PD and a second died from other 
causes. 
Twenty patients (1.6%) developed distant metastases as first 
event (Table 3): none of them had signs of local relapse. 
Altogether eight (0.6%) patients died from breast carcinoma and 
ten (0.8%) died from other causes. 
 



















Table 3: First unfavourable event (89 cases) 
 
 
Table 4: Side effects among 1246 patients
 
 
Local side effects 
Immediate post-operative events
Forty-five patients (3.6%) developed acute haematoma, and 15 
(1.2%) had post-operative infections in the treated portion of the 
breast (Table 4). 
 
Fibrosis
Six patients (0.5%) who received 21 Gy developed severe 
fibrosis, one of them associated with post-surgical haematoma. 
An additional 40 (3.2%) patients suffered from mild fibrosis; the 
development of the fibrosis was progressive during the first 
months after surgery, reaching a maximum at 12 months, 
remained stable for another 6–12 months, and within 36 months 
from surgery slowly regressed. At the time of publication, five 
patients still have clinical evidence of mild fibrosis in the treated 
area. Fourteen patients experienced moderate skin retraction. 
Liponecrosis
A limited number of patients experienced a mild post-operative 
complication, which we defined as 'liponecrosis'. A localized 
collection of brown fluid with skin erythema, with no sign of 



















infection, was the clinical manifestation of this complication. We 
observed 58 (4.7%) cases of liponecrosis 2–4 weeks after 
surgery. This complication was resolved with simple clinical 
care and, in one case, requested surgical curettage of the 
necrotic area. In another case, the surgical scar spontaneously 
opened due to the fluid pressure, but did not need curettage, 
and repair of the breech was achieved after two weeks. 
Liponecrosis involved mainly patients with very fat breasts; the 
age range was 38–79 years (median age 60): 30 patients were 
younger than 60 years, 20 were between 61 and 70, and 8 were 
older than 70. This complication appears to be more frequent in 
patients with a higher proportion of fat tissue in the breast. 
 
Discussion 
In the field of radiation therapy for breast cancer following 
conservative surgery, the question whether the entire breast 
needs to be irradiated or whether it is sufficient to treat a more 
limited volume of tissue surrounding the tumour bed (PBI) has 
become a controversial issue. Recent data show that 80% of 
local recurrences occur in the scar area (true recurrences), 
while the remaining 20% occur in other quadrants (new primary 
carcinomas) [11–13]. Some interesting studies have been 
published, which aimed at testing the impact of partial breast 
irradiation on breast cancer treatment; different radiotherapy 
techniques were used for these studies with controversial 
results. An early trial at the Christie Hospital showed that whole 
breast irradiation was superior compared to partial breast 
irradiation in local control after breast-conserving surgery (10% 
local recurrences compared to 19.5%, respectively) [14]. On the 
contrary, Reitsamer [15], in a non-randomized study, showed 
that the boost given with intra-operative electron radiotherapy is 
superior to the external breast electron boost irradiation. Partial 
breast irradiation can be delivered also with interstitial 
brachytherapy [16–18], and more recently by external sources 
with three-dimensional radiotherapy (3D-RT) and intensity 
modulated radiotherapy (IMRT) [19–20]. 
A report by a study group convened by the National Cancer 
Institute in 2002 [1] concluded that partial breast irradiation is an 
interesting new development in breast cancer radiotherapy and 
deserves to be encouraged. 
IORT gives way to a second controversial issue. Intra-operative 
radiotherapy was first applied nearly a century ago [21] and was 
developed, with interesting results, in the subsequent decades; 
mainly to treat abdominal carcinomas or sarcomas, locally 
advanced or inoperable [22]. The main limitation of the 
procedure is the logistical problem of transferring the sleeping 
patient from the surgical theatre to the radiotherapy department, 
a complicated manoeuvre not easily acceptable to surgeons. 
The recent appearance of mobile linear accelerators, as a result 
of new advances of technological research, has overcome 
these difficulties. 
A new, refined method for intra-operative radiotherapy is 
'intrabeam', which is used in the TARGIT trial. Intrabeam is a 
miniature electron beam-driven x-ray source that provides a 
point source of low-energy x-rays (50 kV maximum) at the tip of 
a 3.2-mm-diameter tube [23]. A phase III randomized trial 
comparing single-dose intra-operative radiotherapy targeted to 
the tumour bed to conventional external radiotherapy in early 
breast carcinoma is presently in progress [24]. 
We decided some ten years ago to combine the two procedures 
(PBI and IORT), considering that the single session procedure 
instead of the conventional six-week course of whole breast 
irradiation, would substantially ease the difficulties of those 
women who have to contend with long waiting lists for RT or live 
far away from a radiotherapy centre. Equally important is that 
this simpler and quicker treatment will cost much less than 
conventional RT for breast cancer patients. 
The ELIOT is a promising feature in breast conservation; the 
reduction of the radiation field makes the exposure of normal 
tissues dramatically lower (Figure 2), and the shortening of the 
radiation course from 5–6 weeks to one session is extremely 
positive in terms of patients’ quality of life. For this reason, we 
included assessment of quality of life as a routine part of the 
ELIOT procedure. 
We began clinical research on ELIOT in 1999. The first task 
was to estimate the single dose of electrons biologically 
equivalent to standard fractionated radiotherapy for breast 
cancer. To do this, we used the linear-quadratic surviving 
fraction model, otherwise known as multi-target surviving 
fraction model, which indicated that a single dose in the range 
20–22 Gy is equivalent to 58–60 Gy delivered in 2 Gy daily 
fractions, five days a week over six weeks (i.e. the dose 
required to control microscopic residual disease after breast 
resection). 
Initially, we began with intra-operative doses lower than this 
level and then increased them. We studied dose levels of 
10,15,17,19 and 21 Gy [24–28]. 
A randomized trial that started on 20 November 2000 is 
enrolling patients older than 48 years affected by unifocal breast 
carcinoma with maximum diameter 2.5 cm. Patients receive 
breast-conserving surgery and are randomized during the 
operation for ELIOT 21 Gy or external fractionated conventional 




















Figure 2: Thoracic wall protection.
radiotherapy (50 Gy whole breast and 10 Gy boost to tumour 
bed). As of November 2007, 1297 patients have been enlisted 
into the trial: 649 patients received conventional radiotherapy 
and 648 received ELIOT. We are still recruiting patients, and the 
follow-up of treated patients is ongoing. As previously 
mentioned, the 1246 patients described in the present paper are 
patients who either did not chose to enter the trial or were 
ineligible. 
The toxicity of ELIOT is low; we had just six cases of severe 
fibrosis that resolved spontaneously within three years of their 
observation. A further 40 (3.2%) cases  of mild fibrosis did not 
cause serious cosmetic impairment. Fourteen cases of skin 
retraction were related both to ELIOT and to poor surgical 
remodelling of the breast. The 58 cases of liponecrosis 
represent an issue we want to clarify with further follow-up; this 
non-severe complication seems unrelated to post-operative 
infection and involved mainly patients with breast tissue largely 
represented by fat. 
A possible contra-indication to the use of ELIOT was the clinical 
involvement of axillary lymph nodes. We believe that there are 
no logical reasons for this position, as a primary carcinoma, 
even with axillary involvement, may be of very limited dimension 
and therefore may be resolved with conserving surgery and 
local radiotherapy. 
The patients' quality of life has not been negatively affected 
according to our routine measurements. In fact, patients usually 
do not even realize that they underwent radiotherapy during 
surgery. 
The cosmetic results were good in the majority of the patients 
both as evaluated by the patients themselves and by the 
doctors. Among the many advantages of ELIOT, we underline 
the following: 
1.  The skin remains intact and any possible plastic surgery 
operation may be easily conducted. 
2. Patients with breast carcinoma who had in the past received 
radiotherapy on the whole breast, either for a previous 
carcinoma conservatively treated, or for a malignant lymphoma, 
are easily treated with breast conservation and ELIOT. Those 
cases, at the appearance of a new primary breast carcinoma, 
are in many centres treated with mastectomy, as breast 
conservation may appear problematic, as post-operative 
radiotherapy cannot be delivered. 
3.  The availability of the radiotherapy machine during surgery 
allows additional doses of radiotherapy to be given if needed for 
specific reasons. For instance, in a few cases where the 
carcinoma was very close to the pectoralis muscle, a specific 
boost in that area was delivered. 
4. In cases when two primary carcinomas are present, it is easy 
to perform two separate resections followed by ELIOT in both 
quadrants. 
5. The major advantage remains the complete change of life for 
patients living in small villages, in the mountains and in the 
islands far away from radiotherapy centres who very often 
decide on a mastectomy, even for a very tiny carcinoma, due to 




















Figure 3: Overall survival.
enormous problem of undergoing daily post-surgical 
radiotherapy at these far away centres. 
6. An additional advantage of ELIOT is that there is no delay in 
administering RT in cases that need adjuvant anthracyclines. 
There is evidence that the delay might increase the risk of local 
recurrences [30–33]. 
7.  Finally, the complete radioprotection will abolish the side 
effects in the lung, and in the contralateral mammary gland of 
conventional whole breast radiotherapy. 
One area of concern in the use of ELIOT is the management of 
positive surgical margins as positivity is discovered at the final 
histology, a few days after surgery and intra-operative 
radiotherapy. The adoption of an extensive breast resection as 
a standard procedure in breast-conserving surgery keeps the 
incidence of positive surgical margins to very low rates. 
Moreover, data from different studies show that margin positivity 
did not influence the rate of local recurrences if effective 
radiotherapy is delivered [34,35]. 
We had five cases with positive margins (two with in situ 
neoplasia) that were not re-resected. All five cases have no 
signs of recurrences 3.9 (1.2–28.1) months after treatment. 
Conclusions 
The survival rate at five years is high (96.5%) (Figure 3). The 
number of breast-cancer-related events observed is low (24 
cases, 1.9%). The frequency of local recurrences appears to be 
similar to that of patients treated with conventional conservative 
surgery and whole breast radiotherapy. The rate of new primary 
carcinomas in other quadrants is expected to be somewhat 
higher after ELIOT than after whole breast radiotherapy but at 
present is equally low (16 cases, 1.3%). 
Our results confirmed the positive impact of ELIOT on patients' 
quality of life: ELIOT is feasible and well accepted. We are 
waiting for the long-term results on local control from the 
ongoing randomized trial in progress at our institute to decide 
whether to adopt the technique in daily (as standard) practice. 
However, as the data from the present large series are 
reassuring (97% of local control and 98.8% survival at five 
years) we believe that, at least for women living far from 
radiotherapy centres and with minimal risk of local recurrence 
(age > 50 and primary carcinoma <1.5 cm.), the ELIOT 
treatment might be considered an option, provided that the 
patient consents to the proposal. 
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